null

null

null

null

null

null

null

null

null

null

null

null

null

Low-to-moderate leverage; ~$750M convertible notes outstanding; 20% rate rise modestly increases refinancing cost but near-term maturities limited

Predominantly fixed-rate convertible debt; 20% rate increase raises cost of future capital raises but minimal immediate P&L impact given cash runway

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) API/raw material sourcing from China-based CMOs; 2) European gene therapy vector manufacturing concentrated in single-region CDMOs

EU (EUR), Japan (JPY), and Brazil (BRL) are key markets; BRL and JPY devaluation risk most material given recent volatility; EU revenue partially hedged

Primary revenues in North America (~70%), EU (~20%), Japan/ROW (~10%); JPY and BRL devaluation pose moderate erosion risk to international net revenues

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High; single CDMO relationships for gene therapy vectors (e.g., Ultragenyx relies on specialized manufacturers) likely represent non-substitutable >30% input cost

Rare disease biopharmaceutical; cloud disruption would impact internal operations but not directly interrupt product manufacturing or commercial sales

30-day cloud termination would disrupt clinical data management, regulatory submissions, and CRM but core drug supply chain is pharma-infrastructure-dependent, not cloud-native

Moderate API coupling risk; regulatory systems (Veeva, SAP) create switching friction but no single proprietary API lock-in that is existential

Not applicable; revenue model is drug sales and milestone payments, not an investment contract; Howey Test risk is null

Very High

Moderate GDPR exposure via EU patient data in clinical trials; CCPA exposure limited; compliance frameworks in place but ongoing regulatory scrutiny likely

Low-to-moderate; rare disease focus means small market share per indication; orphan drug pricing may attract Congressional scrutiny but formal antitrust risk is low

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Predominantly transactional (~85% product sales); milestone/royalty revenues (~15%) provide some recurring character; no true subscription revenue stream

Per-unit drug sales (net product revenue) for approved therapies; milestone payments from partnerships; royalties from out-licensed assets

Orphan drug ultra-high pricing model (~$100K–$3M/year per patient); pricing power constrained by payer pushback and government negotiations in EU/Japan

Moderate-high domestically due to orphan designation and lack of competition; significantly weaker internationally due to HTA/reimbursement negotiations

Gross margins ~60–70% on marketed products; gene therapy programs carry higher COGS diluting blended margins toward 55–65% near-term

No free-rider problem; rare disease patients require prescriptions and payer authorization; adherence-driven revenue is stable but patient population is finite

Sublinear growth potential long-term; commercial infrastructure is largely built; incremental product launches require modest headcount additions relative to revenue uplift

Marginal cost of adding new approved products leverages existing commercial infrastructure; R&D spend remains high and largely fixed per pipeline program

Not applicable; Ultragenyx is not a franchise business model

At 10x scale, patient identification and physician outreach costs decline per patient; payer contracting complexity increases; CAC likely improves but reimbursement friction scales

No meaningful network effects; rare disease drug demand is patient-need-driven, not user-network-driven; durability of revenue tied to clinical differentiation

-37.3% Return on Assets (Negative equity)

High recession resistance; rare disease therapies treating life-threatening conditions are non-discretionary; demand is inelastic to economic cycles

Patients with rare metabolic and genetic diseases (ultra-orphan populations); prescribing physicians are metabolic specialists and pediatric neurologists

Hospital systems, specialty pharmacies, and government/private payers; no single payer represents disclosed >30% concentration but Medicaid/Medicare collectively dominate

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

0.9% CapEx / Revenue (Low-CapEx Asset-Light)

0001515673

RARE